All News

Article

Dual inhibition of IL17A and IL17F in AxSpA

Antoni Chan, MD, PhD

A new target for treatment in AxSpA is the dual inhibition of IL17A and IL17F (IL17A/F). IL17A is a key driver of the inflammation in the AxSpA and Psoriatic Arthritis (PsA). IL17A and its structurally related IL17F share biologic functional properties. Inhibition of both cytokines (IL17A/F) should result in a greater clinical benefit in AxSpA and PsA than IL17A inhibition alone.

TheDaoIndex Tweet
KDAO2011
"FRAX should be done even if DXA T-2.5 score as it will tell you the probability of fracture in the next 10 years" - Dr. M Humphrey Dr. B Humphrey #ACR22 #Osteoporosis Guidelines Session @rheumnow
TheDaoIndex Tweet
KDAO2011
#ACR22 #Osteoporosis Guidelines Case Example: The FRAX score needs to be adjusted (multiply by 1.15 or 1.2) in pts who are expected to have cumulative dose >5 grams/year of steroids @rheumnow https://t.co/wF8LP0iZjw
David Liew Tweet
drdavidliew
Steroid-sparing in PMR: methotrexate most used, but what is the evidence? Christian Dejaco says: variable at best. We need a proper RCT - and it’s on its way. @Sarah_L_Mackie @profbdasgupta @DrMaxYates1 @CatherineL_Hill @drceowen #ACR22 @RheumNow https://t.co/dxaPdVcOPQ
sheila Tweet
RHEUMarampa
Dr. Ogdie proposes a whole-patient care approach to the treat-to-target strategy in SpA with QoL as the most important target. #ACR22 @Rheumnow @rheumarhyme @trishiemd https://t.co/GjLt2Nym3I
TheDaoIndex Tweet
KDAO2011
#ACR22 #GIO #Osteoporosis Guidelines Case: "Young skeletons recover bone loss rapidly after GC are discontinued." In these pts, despite daily pred 10 mg/day, they just needs Ca/Vit D, lifestyle mod, and monitoring. @rheumnow https://t.co/a5DVZoB3l8
TheDaoIndex Tweet
KDAO2011
#ACR22 #GIOP Guidelines Case: In pt < 40 yo who had renal transplant on 7.5 mg/day or higher with low Z score, consult mineral/metabolism expert but you can consider Rx. @rheumnow https://t.co/RJuRi7EPX1
sheila Tweet
RHEUMarampa
Are we giving enough HCQ?🤔 Findings from the study of Dr J Nestor show that ⬇️dose HCQ (</= 5mkd or <400mg/day) is associated w/ ⬆️hospitalizations for #lupus (adj. OR 4.41; 3.48) #ACR22 @RheumNow ABST#1654 @rheumarhyme #ACRBest https://t.co/XCoZgbdOim
TheDaoIndex Tweet
KDAO2011
Is he the only one? Dr. Stone shared that he kept his notes from internship and residency! I kept an old tshirt from college, but this is a new level. #ACR22 @rheumnow https://t.co/Wj9c2Uizxt
Dr. John Cush Tweet
RheumNow
RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Bristol-Myers Squibb. All content chosen by RheumNow & its Faculty.
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×